Home Newsfeeds CL King Downgrades Minerals Technologies to Neutral

CL King Downgrades Minerals Technologies to Neutral

CL King analyst David Silver downgrades Minerals Technologies (NYSE:MTX) from Buy to Neutral.

byBenzinga Newsdesk

August 30, 2022

1 minute read

CL King analyst David Silver downgrades Minerals Technologies (NYSE:MTX) from Buy to Neutral.

Raymond James Maintains Outperform on Franco-Nevada, Lowers Price Target to C$157

By Benzinga Newsdesk

March 17, 10:29 AM

Raymond James analyst Brian MacArthur maintains Franco-Nevada (TSX:FNV) with a Outperform and lowers the price target from C$158 to C$157.

TSX:FNV

Raymond James Maintains Strong Buy on Integral Ad Science, Lowers Price Target to $18

By Benzinga Newsdesk

July 26, 5:50 AM

Raymond James analyst Aaron Kessler maintains Integral Ad Science (NASDAQ:IAS) with a Strong Buy and lowers the price target from $20 to $18.

IAS

ImmunityBio Announces Presentation At ASCO GI 2023 Of Fully Enrolled Trial In Third-Line And Greater Pancreatic Cancer And Update On FDA Type B Meetings Regarding Paths To Registration

By Benzinga Newsdesk

January 19, 10:10 AM

Positive findings in third line and greater metastatic pancreatic cancer patients (N=83) with doubled median overall survival (OS) versus historical OS Median overall survival of 5.8 months and 61% of

IMRX

Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket

By Avi Kapoor

December 19, 9:09 AM

Shares of Motus GI Holdings, Inc. (NASDAQ: MOTS) shares fell sharply in pre-market trading after the company priced its $5 million public offering. Motus GI Holdings shares dipped 46.5% to $1.15 in pre-market trading. Here are some other stocks moving in pre-market trading.

AHI

CL King Downgrades Minerals Technologies to Neutral

Related Posts

Raymond James Maintains Outperform on Franco-Nevada, Lowers Price Target to C$157

Raymond James Maintains Strong Buy on Integral Ad Science, Lowers Price Target to $18

ImmunityBio Announces Presentation At ASCO GI 2023 Of Fully Enrolled Trial In Third-Line And Greater Pancreatic Cancer And Update On FDA Type B Meetings Regarding Paths To Registration

Why Motus GI Holdings Shares Are Trading Lower By Around 46%; Here Are 20 Stocks Moving Premarket